Novo Nordisk's Once‑Weekly CagriSema Proves Superior to Tirzepatide in Head‑to‑Head Weight Loss Trial – REDEFINE 9 Delivers 21.0% Reduction vs Placebo
CompanyDrug

Novo Nordisk’s Once‑Weekly CagriSema Proves Superior to Tirzepatide in Head‑to‑Head Weight Loss Trial – REDEFINE 9 Delivers 21.0% Reduction vs Placebo

Biokin's Bispecific ADC Izalontamab Bretecan Wins Eighth Breakthrough Therapy Designation in China – PD-1 Combo Targets First-Line PD-L1-Positive TNBC
CompanyDeals

Biokin’s Bispecific ADC Izalontamab Bretecan Wins Eighth Breakthrough Therapy Designation in China – PD-1 Combo Targets First-Line PD-L1-Positive TNBC

Hansoh's Selective TYK2 Inhibitor HS‑10374 Hits Co‑Primary Endpoints in Pivotal Phase III Psoriasis Trial – Over Half of Patients Reach PASI 90 at Week 16
CompanyDrug

Hansoh’s Selective TYK2 Inhibitor HS‑10374 Hits Co‑Primary Endpoints in Pivotal Phase III Psoriasis Trial – Over Half of Patients Reach PASI 90 at Week 16

Insilico Medicine Strikes Tens‑of‑Millions‑of‑Dollars AI Collaboration with Frontier Foundation Model Lab – MMAI Gym Framework to Power Generative Biology Models
CompanyDeals

Insilico Medicine Strikes Tens‑of‑Millions‑of‑Dollars AI Collaboration with Frontier Foundation Model Lab – MMAI Gym Framework to Power Generative Biology Models

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented
Policy / Regulatory

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented

Cutia Therapeutics Secures Macao Marketing Approval for CU‑40102 Topical Finasteride Spray – Completing Greater China Rollout in Androgenetic Alopecia
CompanyDrug

Cutia Therapeutics Secures Macao Marketing Approval for CU‑40102 Topical Finasteride Spray – Completing Greater China Rollout in Androgenetic Alopecia

Qilu Pharmaceutical Drops RMB 400 Million Equity Stake in TYK Medicines – But TY‑9591 Licensing and China Commercialization Deal Stays Alive
CompanyDeals

Qilu Pharmaceutical Drops RMB 400 Million Equity Stake in TYK Medicines – But TY‑9591 Licensing and China Commercialization Deal Stays Alive

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening
Policy / Regulatory

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening

IMPACT Therapeutics and Pharmanovia Receive Positive CHMP Opinion for Sepalna (Senaparib) – PARP1/2 Inhibitor Set for EU First‑Line Ovarian Cancer Maintenance
CompanyDrug

IMPACT Therapeutics and Pharmanovia Receive Positive CHMP Opinion for Sepalna (Senaparib) – PARP1/2 Inhibitor Set for EU First‑Line Ovarian Cancer Maintenance

China's NHC Issues Landmark Rare‑Disease Notice – Mandating Province‑Wide Clinics and Quality Control Networks by End‑2026
Policy / Regulatory

China’s NHC Issues Landmark Rare‑Disease Notice – Mandating Province‑Wide Clinics and Quality Control Networks by End‑2026

Staidson Unit BioJeTay Wins NMPA Trial Acceptance for Bemiltenase alfa in Major Surgical Bleeding – First‑in‑Class Snake Venom–Derived Factor X Activator Expands Beyond Hemophilia
CompanyDrug

Staidson Unit BioJeTay Wins NMPA Trial Acceptance for Bemiltenase alfa in Major Surgical Bleeding – First‑in‑Class Snake Venom–Derived Factor X Activator Expands Beyond Hemophilia

Medicovestor Completes Seed Funding Round to Advance Next-Generation Antibody and ADC Pipeline – MC004 Naked Antibody Targets FDA IND Filing by Early 2027
CompanyDeals

Medicovestor Completes Seed Funding Round to Advance Next-Generation Antibody and ADC Pipeline – MC004 Naked Antibody Targets FDA IND Filing by Early 2027